首页 > 最新文献

Zhurnal nevrologii i psikhiatrii imeni S.S. Korsakova最新文献

英文 中文
[Experience of staged and simultaneous bilateral thalamotomy using MR-guided focused ultrasound in the treatment of essential tremor]. [核磁共振引导下聚焦超声分阶段同步双侧丘脑切开术治疗特发性震颤的经验]。
Q3 Medicine Pub Date : 2023-01-01 DOI: 10.17116/jnevro202312307165
D I Nabiullina, R M Galimova, S N Illarioshkin, I V Buzaev, Sh M Safin, G N Akhmadeeva, N R Mukhamadeeva, D K Krekotin

Objective: To show that effective and safe bilateral MR-guided focused ultrasound (MRgFUS) treatment of essential tremor (ET) is achievable.

Material and methods: Four male patients underwent bilateral thalamotomy. Two patients underwent staged thalamotomy, with the ≥12 month interval between operations. Two patients underwent simultaneous bilateral thalamotomy.

Results: After six months, all patients noted a significant reduction in symptoms on both sides: when assessing tremors with the Clinical Rating Scale for Tremor, the severity of hyperkinesis decreased by 57.5-69.7%. We did not observe any complications in any of the cases.

Conclusion: Our experience indicates that simultaneous bilateral MRI-guided focused ultrasound treatment of ET can be performed safely and effectively. Further research is necessary to estimate the effectiveness and adverse effect rates.

目的:探讨双侧磁共振引导聚焦超声(MRgFUS)治疗特发性震颤(ET)的有效性和安全性。材料与方法:4例男性患者行双侧丘脑切开术。2例患者分期行丘脑切开术,手术间隔≥12个月。2例患者同时行双侧丘脑切开术。结果:6个月后,所有患者的双侧症状均显著减轻:当用震颤临床评定量表评估震颤时,运动亢进的严重程度降低了57.5-69.7%。我们没有观察到任何病例的并发症。结论:我们的经验表明,同时双侧mri引导下的聚焦超声治疗ET是安全有效的。需要进一步的研究来评估其有效性和不良反应发生率。
{"title":"[Experience of staged and simultaneous bilateral thalamotomy using MR-guided focused ultrasound in the treatment of essential tremor].","authors":"D I Nabiullina,&nbsp;R M Galimova,&nbsp;S N Illarioshkin,&nbsp;I V Buzaev,&nbsp;Sh M Safin,&nbsp;G N Akhmadeeva,&nbsp;N R Mukhamadeeva,&nbsp;D K Krekotin","doi":"10.17116/jnevro202312307165","DOIUrl":"https://doi.org/10.17116/jnevro202312307165","url":null,"abstract":"<p><strong>Objective: </strong>To show that effective and safe bilateral MR-guided focused ultrasound (MRgFUS) treatment of essential tremor (ET) is achievable.</p><p><strong>Material and methods: </strong>Four male patients underwent bilateral thalamotomy. Two patients underwent staged thalamotomy, with the ≥12 month interval between operations. Two patients underwent simultaneous bilateral thalamotomy.</p><p><strong>Results: </strong>After six months, all patients noted a significant reduction in symptoms on both sides: when assessing tremors with the Clinical Rating Scale for Tremor, the severity of hyperkinesis decreased by 57.5-69.7%. We did not observe any complications in any of the cases.</p><p><strong>Conclusion: </strong>Our experience indicates that simultaneous bilateral MRI-guided focused ultrasound treatment of ET can be performed safely and effectively. Further research is necessary to estimate the effectiveness and adverse effect rates.</p>","PeriodicalId":24030,"journal":{"name":"Zhurnal nevrologii i psikhiatrii imeni S.S. Korsakova","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2023-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"9872265","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
[Treatment of cognitive, behavioral and mental disorders in patients with vascular dementia: results of a multicenter, randomized, double-blind, placebo-controlled clinical trial]. [血管性痴呆患者认知、行为和精神障碍的治疗:一项多中心、随机、双盲、安慰剂对照临床试验的结果]。
Q3 Medicine Pub Date : 2023-01-01 DOI: 10.17116/jnevro202312307141
O N Tkacheva, E A Mkhitaryan, I V Kolykhalov, A N Belova, O V Kolokolov, L G Zaslavsky, N M Khasanova, L R Akhmadeeva, E I Bogdanov

Objective: Evaluation of the efficacy and safety of Prospect in the treatment of cognitive, behavioral and mental disorders in patients with vascular dementia (VSD).

Material and methods: In a double-blind, placebo-controlled, parallel-group randomised clinical trial, 406 patients aged 60-85 years old with a diagnosis of mild/moderate vascular dementia (10-24 on the Mini-Mental State Examination (MMSE)) and without signs of depression (Cornell Scale for Depression in Dementia (CSDD) scores ≤10) were included. At Visit 1, complaints and medical history were collected, vital signs were recorded, cognitive impairment was assessed using MMSE and MoCA, NPI-C and CSDD were completed, and an MRI brain scan was performed. Patients were randomised into two groups: patients in group 1 received Prospekta in a dosage of 2 tablets two times a day for 24 weeks, and patients in group 2 received Placebo according to the study drug regimen.

Results: Patients in both groups had no differences in demographic and baseline clinical characteristics. Administration of Prospekta for 24 weeks reduced cognitive impairment in patients with vascular dementia compared to the placebo group. The mean MoCA score increased from 17.0±3.6 [17.1±3.6] to 20.5±4.7 [20.4±4.7] in patients treated with Prospekta, whereas it increased from 17.3±3.7 [17.3±3.8] to 19.2±4.9 [19.2±5.0] in the Placebo group. Treatment with the medication also reduced the severity of neuropsychiatric symptoms as measured by the NPI-C scale. The mean score on this scale decreased from 57.0±26.7 [56.7±25.4] to 39.8±23.6 [39.8±23.5] in the Prospekta group and from 55.5±25.5 [55.3±24.4] to 42.8±27.6 [42.3±25.3] in the Placebo group. The difference in mean MoCA and NPI-C scores between the Prospekta and Placebo groups was statistically significant.

Conclusion: Prospekta is an effective and safe drug for treating cognitive, behavioural and mental disturbances in patients with vascular dementia.

目的:评价Prospect治疗血管性痴呆(VSD)患者认知、行为和精神障碍的疗效和安全性。材料和方法:在一项双盲、安慰剂对照、平行组随机临床试验中,纳入406名年龄在60-85岁、诊断为轻度/中度血管性痴呆(Mini-Mental State Examination, MMSE)的患者(10-24分),无抑郁症状(Cornell Scale for depression In dementia, CSDD)评分≤10分)。就诊1时,收集主诉和病史,记录生命体征,用MMSE和MoCA评估认知功能障碍,完成NPI-C和CSDD,并进行MRI脑扫描。患者随机分为两组:1组患者接受Prospekta治疗,剂量为2片,每天2次,持续24周;2组患者根据研究药物方案接受安慰剂治疗。结果:两组患者在人口学和基线临床特征上无差异。与安慰剂组相比,服用Prospekta 24周可减少血管性痴呆患者的认知障碍。Prospekta组MoCA评分从17.0±3.6[17.1±3.6]上升至20.5±4.7[20.4±4.7],而安慰剂组MoCA评分从17.3±3.7[17.3±3.8]上升至19.2±4.9[19.2±5.0]。用NPI-C量表测量,用药物治疗也降低了神经精神症状的严重程度。Prospekta组的平均评分从57.0±26.7[56.7±25.4]降至39.8±23.6[39.8±23.5],安慰剂组从55.5±25.5[55.3±24.4]降至42.8±27.6[42.3±25.3]。Prospekta组和安慰剂组的MoCA和NPI-C平均评分差异有统计学意义。结论:Prospekta是一种安全有效的治疗血管性痴呆患者认知、行为和精神障碍的药物。
{"title":"[Treatment of cognitive, behavioral and mental disorders in patients with vascular dementia: results of a multicenter, randomized, double-blind, placebo-controlled clinical trial].","authors":"O N Tkacheva,&nbsp;E A Mkhitaryan,&nbsp;I V Kolykhalov,&nbsp;A N Belova,&nbsp;O V Kolokolov,&nbsp;L G Zaslavsky,&nbsp;N M Khasanova,&nbsp;L R Akhmadeeva,&nbsp;E I Bogdanov","doi":"10.17116/jnevro202312307141","DOIUrl":"https://doi.org/10.17116/jnevro202312307141","url":null,"abstract":"<p><strong>Objective: </strong>Evaluation of the efficacy and safety of Prospect in the treatment of cognitive, behavioral and mental disorders in patients with vascular dementia (VSD).</p><p><strong>Material and methods: </strong>In a double-blind, placebo-controlled, parallel-group randomised clinical trial, 406 patients aged 60-85 years old with a diagnosis of mild/moderate vascular dementia (10-24 on the Mini-Mental State Examination (MMSE)) and without signs of depression (Cornell Scale for Depression in Dementia (CSDD) scores ≤10) were included. At Visit 1, complaints and medical history were collected, vital signs were recorded, cognitive impairment was assessed using MMSE and MoCA, NPI-C and CSDD were completed, and an MRI brain scan was performed. Patients were randomised into two groups: patients in group 1 received Prospekta in a dosage of 2 tablets two times a day for 24 weeks, and patients in group 2 received Placebo according to the study drug regimen.</p><p><strong>Results: </strong>Patients in both groups had no differences in demographic and baseline clinical characteristics. Administration of Prospekta for 24 weeks reduced cognitive impairment in patients with vascular dementia compared to the placebo group. The mean MoCA score increased from 17.0±3.6 [17.1±3.6] to 20.5±4.7 [20.4±4.7] in patients treated with Prospekta, whereas it increased from 17.3±3.7 [17.3±3.8] to 19.2±4.9 [19.2±5.0] in the Placebo group. Treatment with the medication also reduced the severity of neuropsychiatric symptoms as measured by the NPI-C scale. The mean score on this scale decreased from 57.0±26.7 [56.7±25.4] to 39.8±23.6 [39.8±23.5] in the Prospekta group and from 55.5±25.5 [55.3±24.4] to 42.8±27.6 [42.3±25.3] in the Placebo group. The difference in mean MoCA and NPI-C scores between the Prospekta and Placebo groups was statistically significant.</p><p><strong>Conclusion: </strong>Prospekta is an effective and safe drug for treating cognitive, behavioural and mental disturbances in patients with vascular dementia.</p>","PeriodicalId":24030,"journal":{"name":"Zhurnal nevrologii i psikhiatrii imeni S.S. Korsakova","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2023-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"9872267","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 1
[An effect of antipsychotic and anticholinergic treatment on cognitive function in patients with schizophrenia]. [抗精神病和抗胆碱能治疗对精神分裂症患者认知功能的影响]。
Q3 Medicine Pub Date : 2023-01-01 DOI: 10.17116/jnevro202312307180
M A Tumova, A A Stepanova, Y S Zazulina, Z T Guseinova, M M Zaitseva, I V Dyment, A P Kotsyubinsky, M V Ivanov

Objective: To reveal the relationships between antipsychotic and anticholinergic drugs and cognitive functions in patients with schizophrenia.

Material and methods: The observational prospective study was conducted at the Bekhterev National Medical Center of Psychiatry and Neurology. The study involved 41 patients (22 men and 19 women) with paranoid schizophrenia, according to ICD 10 criteria, aged 30.12±8.24 years on stable antipsychotic monotherapy or in combination with anticholinergic drug (trihexiphenidyl). Cognitive functions were assessed using the «Brief Assessment of Cognitive Function in Patients with Schizophrenia» (BACS) scale, severity of mental state and extrapyramidal disturbances were measured using the «Positive and Negative Syndrome Scale (PANSS) and the Simpson-Angus Scale for Assessment of Extrapyramidal Side Effects (SAS). All examination procedures were performed twice at weeks 2 and 8 of therapy. Patients were divided into 2 groups according to the type of antipsychotic therapy. Twelve patients received first generation antipsychotics (FGAs) (group 1), 29 patients received second generation antipsychotics (SGAs) (group 2).

Results: Patients receiving SGAs had a significant decrease in the overall SAS score at week 8 of therapy compared with data at week 2, and there was an improvement in cognitive function, unlike patients receiving FGAs. There were also changes on BACS tests the digit sequencing (V=51.5, p=0.007), token motor task (V=75.5, p=0.007) and Tower of London (V=52, p=0.027) only in patients of group 2.

Conclusion: The improved tolerance to the drug, as well as cognitive measures, was shown in patients taking SGAs by week 8. Our study confirms the importance of adhering to the minimum effective dose of antipsychotic drugs for the treatment of schizophrenia to prevent cognitive impairment, and to give preference to SGAs in the choice of treatment.

目的:探讨抗精神病药物和抗胆碱能药物与精神分裂症患者认知功能的关系。材料和方法:观察性前瞻性研究在别赫捷列夫国家精神病学和神经病学医学中心进行。本研究纳入41例偏执型精神分裂症患者(男22例,女19例),符合ICD 10标准,年龄30.12±8.24岁,采用稳定的抗精神病单药治疗或联合抗胆碱能药物(三己苯肼)治疗。认知功能采用《精神分裂症患者认知功能简要评估》(BACS)量表进行评估,精神状态和锥体外系障碍的严重程度采用《阳性和阴性综合征量表》(PANSS)和《辛普森-安格斯锥体外系副作用评估量表》(SAS)进行测量。所有检查程序在治疗第2周和第8周进行两次。根据抗精神病药物治疗类型将患者分为两组。12例患者接受第一代抗精神病药(FGAs)治疗(1组),29例患者接受第二代抗精神病药(SGAs)治疗(2组)。结果:与第2周的数据相比,接受SGAs治疗的患者在治疗第8周的SAS总分显著下降,认知功能有所改善,与接受FGAs治疗的患者不同。仅在2组患者的BACS测试中,数字排序(V=51.5, p=0.007)、标记运动任务(V=75.5, p=0.007)和伦敦塔(V=52, p=0.027)也有变化。结论:服用SGAs的患者在第8周时对药物的耐受性和认知功能均有所改善。我们的研究证实了在精神分裂症治疗中坚持最低有效剂量的抗精神病药物对预防认知障碍的重要性,并在治疗选择中优先考虑SGAs。
{"title":"[An effect of antipsychotic and anticholinergic treatment on cognitive function in patients with schizophrenia].","authors":"M A Tumova,&nbsp;A A Stepanova,&nbsp;Y S Zazulina,&nbsp;Z T Guseinova,&nbsp;M M Zaitseva,&nbsp;I V Dyment,&nbsp;A P Kotsyubinsky,&nbsp;M V Ivanov","doi":"10.17116/jnevro202312307180","DOIUrl":"https://doi.org/10.17116/jnevro202312307180","url":null,"abstract":"<p><strong>Objective: </strong>To reveal the relationships between antipsychotic and anticholinergic drugs and cognitive functions in patients with schizophrenia.</p><p><strong>Material and methods: </strong>The observational prospective study was conducted at the Bekhterev National Medical Center of Psychiatry and Neurology. The study involved 41 patients (22 men and 19 women) with paranoid schizophrenia, according to ICD 10 criteria, aged 30.12±8.24 years on stable antipsychotic monotherapy or in combination with anticholinergic drug (trihexiphenidyl). Cognitive functions were assessed using the «Brief Assessment of Cognitive Function in Patients with Schizophrenia» (BACS) scale, severity of mental state and extrapyramidal disturbances were measured using the «Positive and Negative Syndrome Scale (PANSS) and the Simpson-Angus Scale for Assessment of Extrapyramidal Side Effects (SAS). All examination procedures were performed twice at weeks 2 and 8 of therapy. Patients were divided into 2 groups according to the type of antipsychotic therapy. Twelve patients received first generation antipsychotics (FGAs) (group 1), 29 patients received second generation antipsychotics (SGAs) (group 2).</p><p><strong>Results: </strong>Patients receiving SGAs had a significant decrease in the overall SAS score at week 8 of therapy compared with data at week 2, and there was an improvement in cognitive function, unlike patients receiving FGAs. There were also changes on BACS tests the digit sequencing (V=51.5, <i>p</i>=0.007), token motor task (V=75.5, <i>p</i>=0.007) and Tower of London (V=52, <i>p</i>=0.027) only in patients of group 2.</p><p><strong>Conclusion: </strong>The improved tolerance to the drug, as well as cognitive measures, was shown in patients taking SGAs by week 8. Our study confirms the importance of adhering to the minimum effective dose of antipsychotic drugs for the treatment of schizophrenia to prevent cognitive impairment, and to give preference to SGAs in the choice of treatment.</p>","PeriodicalId":24030,"journal":{"name":"Zhurnal nevrologii i psikhiatrii imeni S.S. Korsakova","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2023-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"9885939","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
[Neuropathic pain caused by the toxic effect of chemotherapy in patients with malignant neoplasms]. 【恶性肿瘤患者化疗毒性作用引起的神经性疼痛】。
Q3 Medicine Pub Date : 2023-01-01 DOI: 10.17116/jnevro20231230517
S V Chubykina, M U Tatarinova, G G Avakyan

This article discusses chemotherapy-induced peripheral neuropathic pain (CIPNP) and its associated neuropathic pain syndrome that occurs in patients with malignant neoplasms (MN) during cytostatic therapy. The overall prevalence of CIPNP in patients with malignant neoplasms associated with chemotherapy with neurotoxic drugs is estimated, according to various sources, to be about 70%. The pathophysiological mechanisms of CIPNP have not been fully studied, but it is known that they are based on: impaired axonal transport, oxidative stress, induction of apoptosis, DNA damage, dysfunction of voltage-gated ion channels, and central mechanisms. It is important to recognize CIPNP in the clinical symptoms of patients with cancer treated with cytostatics, since these disorders can lead to serious restrictions in the motor, sensory and autonomic functions of the upper and lower extremities, as well as reduce the quality of life and daily functioning of such patients, forcing them to adjust the dose of chemotherapy drugs, transfer the next cycles and even interrupt the treatment of cancer carried out according to vital needs. In addition to the clinical examination, scales and questionnaires have been developed to identify symptoms of CIPNP, but it is most important for neurological and oncological specialists to know and be able to recognize such symptoms in patients. The mandatory research methods for identifying the symptoms of polyneuropathy include electroneuromyography (ENMG), which allows you to assess muscle activity, functional characteristics and the state of the function of peripheral nerves. The methods used to reduce symptoms are screening patients for the development of CIPNP and identifying patients at high risk of CIPNP and, if necessary, reducing the dose or changing cytostatics. Methods for correcting this disorder using different classes of drugs require more detailed study and further research.

本文讨论了化疗引起的周围神经性疼痛(CIPNP)及其相关的神经性疼痛综合征,发生在恶性肿瘤(MN)患者在细胞抑制剂治疗期间。根据各种来源估计,在与神经毒性药物化疗相关的恶性肿瘤患者中,CIPNP的总体患病率约为70%。CIPNP的病理生理机制尚未得到充分研究,但已知其基于:轴突转运受损、氧化应激、细胞凋亡诱导、DNA损伤、电压门控离子通道功能障碍和中枢机制。在接受细胞抑制剂治疗的癌症患者的临床症状中认识到CIPNP是很重要的,因为这些疾病会导致上肢和下肢运动、感觉和自主神经功能的严重限制,并降低患者的生活质量和日常功能,迫使他们调整化疗药物的剂量,转移下一个周期,甚至中断根据生命需要进行的癌症治疗。除了临床检查外,还开发了量表和问卷来识别CIPNP的症状,但最重要的是神经学和肿瘤学专家要知道并能够识别患者的这些症状。识别多神经病变症状的强制性研究方法包括神经肌电图(ENMG),它允许您评估肌肉活动,功能特征和周围神经功能状态。用于减轻症状的方法是筛查发生CIPNP的患者,识别发生CIPNP的高风险患者,必要时减少剂量或改变细胞抑制剂。使用不同类别的药物纠正这种疾病的方法需要更详细的研究和进一步的研究。
{"title":"[Neuropathic pain caused by the toxic effect of chemotherapy in patients with malignant neoplasms].","authors":"S V Chubykina,&nbsp;M U Tatarinova,&nbsp;G G Avakyan","doi":"10.17116/jnevro20231230517","DOIUrl":"https://doi.org/10.17116/jnevro20231230517","url":null,"abstract":"<p><p>This article discusses chemotherapy-induced peripheral neuropathic pain (CIPNP) and its associated neuropathic pain syndrome that occurs in patients with malignant neoplasms (MN) during cytostatic therapy. The overall prevalence of CIPNP in patients with malignant neoplasms associated with chemotherapy with neurotoxic drugs is estimated, according to various sources, to be about 70%. The pathophysiological mechanisms of CIPNP have not been fully studied, but it is known that they are based on: impaired axonal transport, oxidative stress, induction of apoptosis, DNA damage, dysfunction of voltage-gated ion channels, and central mechanisms. It is important to recognize CIPNP in the clinical symptoms of patients with cancer treated with cytostatics, since these disorders can lead to serious restrictions in the motor, sensory and autonomic functions of the upper and lower extremities, as well as reduce the quality of life and daily functioning of such patients, forcing them to adjust the dose of chemotherapy drugs, transfer the next cycles and even interrupt the treatment of cancer carried out according to vital needs. In addition to the clinical examination, scales and questionnaires have been developed to identify symptoms of CIPNP, but it is most important for neurological and oncological specialists to know and be able to recognize such symptoms in patients. The mandatory research methods for identifying the symptoms of polyneuropathy include electroneuromyography (ENMG), which allows you to assess muscle activity, functional characteristics and the state of the function of peripheral nerves. The methods used to reduce symptoms are screening patients for the development of CIPNP and identifying patients at high risk of CIPNP and, if necessary, reducing the dose or changing cytostatics. Methods for correcting this disorder using different classes of drugs require more detailed study and further research.</p>","PeriodicalId":24030,"journal":{"name":"Zhurnal nevrologii i psikhiatrii imeni S.S. Korsakova","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2023-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"9995051","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
[The use of the Mini-Cog, MMSE, and GPCOG tests in domestic clinical practice for the evaluation of cognitive disorders in elderly and senile patients: the results of a survey of experts' opinions]. [Mini-Cog、MMSE、GPCOG测试在国内临床评价中老年患者认知障碍的应用:专家意见调查结果]。
Q3 Medicine Pub Date : 2023-01-01 DOI: 10.17116/jnevro202312307155
T I Ionova, E V Frolova, K V Ovakimyan, E A Mkhitaryan, O N Tkacheva, D L Logunov, A Yu Oskova, E A Vasileva, Yu V Zhitkova, A A Gasparyan, K V Lunev, E A Luneva, N M Porfirieva, T P Nikitina

Objective: To explore the experts' opinion on the feasibility of using Mini-Kog, MMSE and GPCOG tests for screening assessment of cognitive impairment in elderly and senile patients at the primary stage of medical care, as well as to compare different characteristics of these tests according to experts' opinion.

Material and methods: The survey of specialists was carried out on the basis of 6 Medical Centers. Prior to the survey, specialists tested cognitive functions in elderly and senile patients during routine visits undergoing routine admission using Mini-Kog, MMSE and GPCOG tests, as well as interviewed their relatives using the corresponding section of the GPCOG. During the survey, specialists filled out a special physician checklist containing items for indicating socio-demographic information and questions regarding the use of tests for assessing cognitive functions in elderly and senile patients in daily clinical practice.

Results: The survey involved 40 specialists from different cities of Russia (mean age±SD - 38.6±14.3 years, 82.5% - women). Elderly and senile patients accounted for the predominant proportion (76-100%) of all followed-up patients. All physicians considered it important to conduct a cognitive assessment in elderly patients and they have to use various cognitive tests in their practice. According to most experts, among the Mini-Kog, MMSE and GPCOG tests, all three tools are informative, convenient and suitable for screening cognitive impairment in geriatric patients. The MMSE test is more informative and convenient. Mini-Kog, compared to the other two tools, is the simplest and most time-efficient tool that is also better perceived by patients. An advantage of the GPCOG is the possibility of participation of informants in the assessment of cognitive functions in older patients.

Conclusion: The findings could be used in further research focused on improving the approaches for early detection of cognitive impairment in geriatric patients by primary care physicians.

目的:探讨专家对采用mini - kg、MMSE和GPCOG试验筛查评估老年及老年患者初级医疗阶段认知功能障碍的可行性的意见,并根据专家意见比较这些试验的不同特点。材料与方法:以6家医疗中心为调查对象进行专家调查。在调查之前,专家使用Mini-Kog、MMSE和GPCOG测试测试了常规就诊的老年和老年患者的认知功能,并使用GPCOG的相应部分采访了他们的亲属。在调查期间,专家填写了一份特殊的医生检查表,其中包含社会人口统计信息和关于在日常临床实践中使用评估老年人和老年患者认知功能的测试的问题。结果:调查对象为40名来自俄罗斯不同城市的专家(平均年龄±SD - 38.6±14.3岁,女性占82.5%)。在所有随访患者中,中老年患者占主要比例(76-100%)。所有的医生都认为对老年患者进行认知评估很重要,他们必须在实践中使用各种认知测试。大多数专家认为,在mini - kg、MMSE和GPCOG测试中,这三种工具都是信息丰富、方便且适合筛查老年患者认知障碍的工具。MMSE测试的信息量更大,也更方便。与其他两种工具相比,Mini-Kog是最简单、最省时的工具,也更容易被患者接受。GPCOG的一个优点是可以让信息提供者参与对老年患者认知功能的评估。结论:本研究结果可为进一步提高初级保健医生对老年患者认知功能障碍的早期检测方法提供参考。
{"title":"[The use of the Mini-Cog, MMSE, and GPCOG tests in domestic clinical practice for the evaluation of cognitive disorders in elderly and senile patients: the results of a survey of experts' opinions].","authors":"T I Ionova,&nbsp;E V Frolova,&nbsp;K V Ovakimyan,&nbsp;E A Mkhitaryan,&nbsp;O N Tkacheva,&nbsp;D L Logunov,&nbsp;A Yu Oskova,&nbsp;E A Vasileva,&nbsp;Yu V Zhitkova,&nbsp;A A Gasparyan,&nbsp;K V Lunev,&nbsp;E A Luneva,&nbsp;N M Porfirieva,&nbsp;T P Nikitina","doi":"10.17116/jnevro202312307155","DOIUrl":"https://doi.org/10.17116/jnevro202312307155","url":null,"abstract":"<p><strong>Objective: </strong>To explore the experts' opinion on the feasibility of using Mini-Kog, MMSE and GPCOG tests for screening assessment of cognitive impairment in elderly and senile patients at the primary stage of medical care, as well as to compare different characteristics of these tests according to experts' opinion.</p><p><strong>Material and methods: </strong>The survey of specialists was carried out on the basis of 6 Medical Centers. Prior to the survey, specialists tested cognitive functions in elderly and senile patients during routine visits undergoing routine admission using Mini-Kog, MMSE and GPCOG tests, as well as interviewed their relatives using the corresponding section of the GPCOG. During the survey, specialists filled out a special physician checklist containing items for indicating socio-demographic information and questions regarding the use of tests for assessing cognitive functions in elderly and senile patients in daily clinical practice.</p><p><strong>Results: </strong>The survey involved 40 specialists from different cities of Russia (mean age±SD - 38.6±14.3 years, 82.5% - women). Elderly and senile patients accounted for the predominant proportion (76-100%) of all followed-up patients. All physicians considered it important to conduct a cognitive assessment in elderly patients and they have to use various cognitive tests in their practice. According to most experts, among the Mini-Kog, MMSE and GPCOG tests, all three tools are informative, convenient and suitable for screening cognitive impairment in geriatric patients. The MMSE test is more informative and convenient. Mini-Kog, compared to the other two tools, is the simplest and most time-efficient tool that is also better perceived by patients. An advantage of the GPCOG is the possibility of participation of informants in the assessment of cognitive functions in older patients.</p><p><strong>Conclusion: </strong>The findings could be used in further research focused on improving the approaches for early detection of cognitive impairment in geriatric patients by primary care physicians.</p>","PeriodicalId":24030,"journal":{"name":"Zhurnal nevrologii i psikhiatrii imeni S.S. Korsakova","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2023-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"10379497","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 1
[Slow-wave sleep and the possibilities of modern insomnia therapy]. [慢波睡眠和现代失眠疗法的可能性]。
Q3 Medicine Pub Date : 2023-01-01 DOI: 10.17116/jnevro202312308149
V E Medvedev, N V Titova, I V Milyukhina, F Sh Shagiakhmetov, R R Borukaev, I V Kolyvanova

Effective therapy of insomnia, especially chronic insomnia, is one of the most pressing neuropsychiatric problems. Unfortunately, at present in the Russian Federation, as in most other countries of the world, there are no officially approved drugs for long-term treatment of insomnia. In this regard, the use of medical sedation agents that do not have restrictions on the duration of use is of considerable interest. This review considers drugs of various psychopharmacological classes, one way or another used in practice for the correction of sleep disorders, especially in patients with underlying comorbid pathology.

失眠的有效治疗,特别是慢性失眠,是最紧迫的神经精神问题之一。不幸的是,目前在俄罗斯联邦和世界上大多数其他国家一样,没有正式批准的长期治疗失眠的药物。在这方面,使用对使用时间没有限制的医用镇静剂具有相当大的意义。本综述考虑了各种精神药理学类别的药物,在实践中以一种或另一种方式用于纠正睡眠障碍,特别是在有潜在共病病理的患者中。
{"title":"[Slow-wave sleep and the possibilities of modern insomnia therapy].","authors":"V E Medvedev,&nbsp;N V Titova,&nbsp;I V Milyukhina,&nbsp;F Sh Shagiakhmetov,&nbsp;R R Borukaev,&nbsp;I V Kolyvanova","doi":"10.17116/jnevro202312308149","DOIUrl":"https://doi.org/10.17116/jnevro202312308149","url":null,"abstract":"<p><p>Effective therapy of insomnia, especially chronic insomnia, is one of the most pressing neuropsychiatric problems. Unfortunately, at present in the Russian Federation, as in most other countries of the world, there are no officially approved drugs for long-term treatment of insomnia. In this regard, the use of medical sedation agents that do not have restrictions on the duration of use is of considerable interest. This review considers drugs of various psychopharmacological classes, one way or another used in practice for the correction of sleep disorders, especially in patients with underlying comorbid pathology.</p>","PeriodicalId":24030,"journal":{"name":"Zhurnal nevrologii i psikhiatrii imeni S.S. Korsakova","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2023-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"10517872","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
[Piecewise linear regression model of hemostasis dynamics in donors and patients with schizophrenia]. 献血者与精神分裂症患者止血动态的分段线性回归模型
Q3 Medicine Pub Date : 2023-01-01 DOI: 10.17116/jnevro2023123011111
O V Senko, O S Brusov, L I Ponomareva, I A Matveev, N S Karpova, A V Kuznetsova, M Yu Salmanov

Objective: This work is to develop and use a new approach to the analysis of differences between the velocity profiles of registered light signals in groups of patients with schizophrenia and healthy donors.

Material and methods: The present study involved 62 patients (all female) with schizophrenia or schizoaffective disorders in the acute period (observational study - 2016-2017). 44 patients were diagnosed with paranoid schizophrenia with an attack-progredient type of course (F20.01 according to ICD-10) or with a continuous type of course (F20.02). The fibrinodynamics test (FD) was performed on the T-2 thrombodynamics device (Hemacore LLC, Moscow), which makes it possible to monitor the processes of coagulation and fibrinolysis in the cuvette channels filled with fresh blood plasma. The result of the test are the brightness profiles of the clot.

Results: In the proposed approach, each profile is characterized by a vector of distances between it and other analyzed profiles. At that the distances between the profiles are calculated as the sum of the modules of differences at different points of the observation interval. This method makes it possible to overcome a certain loss of information that occurs when using a standard method based on the calculation of several parameters that characterize the analyzed velocity profiles. The method includes the construction of all kinds of statistically significant piecewise linear regression models that link the distances to two profiles. The velocity profiles corresponding to the points lying on opposite sides of the break point of such models have significantly different shapes. In practice, it turns out that for many piecewise linear regression models, the break points also significantly separate the velocity profiles for the compared groups of donors and patients with schizophrenia. Statistically significant deviations at the level p≤0.01 exist for 16.1% of 3143 statistically significant piecewise linear models.

Conclusion: The developed method makes it possible to visually establish the relationship between the shape of the velocity profile and the presence of the disease.

目的:建立并应用一种新的方法来分析精神分裂症患者和健康供体群体中记录光信号的速度分布差异。材料和方法:本研究纳入62例急性期精神分裂症或分裂情感性障碍患者(均为女性)(观察性研究- 2016-2017)。44例患者被诊断为偏执型精神分裂症,病程为发作进行性病程(根据ICD-10分为F20.01)或连续型病程(根据ICD-10分为F20.02)。纤维蛋白动力学试验(FD)是在T-2血栓动力学装置(Hemacore LLC, Moscow)上进行的,这使得在充满新鲜血浆的试管通道中监测凝血和纤维蛋白溶解过程成为可能。测试的结果是凝块的亮度曲线。结果:在提出的方法中,每个剖面都由它与其他分析剖面之间的距离向量来表征。此时,轮廓之间的距离计算为观测区间不同点差模的和。该方法可以克服在使用基于计算所分析的速度剖面特征的几个参数的标准方法时发生的某些信息丢失。该方法包括建立各种统计上显著的分段线性回归模型,将距离与两个剖面联系起来。这两种模型的断点两侧点对应的速度剖面形状有明显不同。在实践中,对于许多分段线性回归模型,断点也显著地分离了供体组和精神分裂症患者组的速度分布。在3143个分段线性模型中,有16.1%的模型在p≤0.01水平上存在统计学显著偏差。结论:所建立的方法可以直观地建立速度剖面形状与疾病存在之间的关系。
{"title":"[Piecewise linear regression model of hemostasis dynamics in donors and patients with schizophrenia].","authors":"O V Senko,&nbsp;O S Brusov,&nbsp;L I Ponomareva,&nbsp;I A Matveev,&nbsp;N S Karpova,&nbsp;A V Kuznetsova,&nbsp;M Yu Salmanov","doi":"10.17116/jnevro2023123011111","DOIUrl":"https://doi.org/10.17116/jnevro2023123011111","url":null,"abstract":"<p><strong>Objective: </strong>This work is to develop and use a new approach to the analysis of differences between the velocity profiles of registered light signals in groups of patients with schizophrenia and healthy donors.</p><p><strong>Material and methods: </strong>The present study involved 62 patients (all female) with schizophrenia or schizoaffective disorders in the acute period (observational study - 2016-2017). 44 patients were diagnosed with paranoid schizophrenia with an attack-progredient type of course (F20.01 according to ICD-10) or with a continuous type of course (F20.02). The fibrinodynamics test (FD) was performed on the T-2 thrombodynamics device (Hemacore LLC, Moscow), which makes it possible to monitor the processes of coagulation and fibrinolysis in the cuvette channels filled with fresh blood plasma. The result of the test are the brightness profiles of the clot.</p><p><strong>Results: </strong>In the proposed approach, each profile is characterized by a vector of distances between it and other analyzed profiles. At that the distances between the profiles are calculated as the sum of the modules of differences at different points of the observation interval. This method makes it possible to overcome a certain loss of information that occurs when using a standard method based on the calculation of several parameters that characterize the analyzed velocity profiles. The method includes the construction of all kinds of statistically significant piecewise linear regression models that link the distances to two profiles. The velocity profiles corresponding to the points lying on opposite sides of the break point of such models have significantly different shapes. In practice, it turns out that for many piecewise linear regression models, the break points also significantly separate the velocity profiles for the compared groups of donors and patients with schizophrenia. Statistically significant deviations at the level <i>p</i>≤0.01 exist for 16.1% of 3143 statistically significant piecewise linear models.</p><p><strong>Conclusion: </strong>The developed method makes it possible to visually establish the relationship between the shape of the velocity profile and the presence of the disease.</p>","PeriodicalId":24030,"journal":{"name":"Zhurnal nevrologii i psikhiatrii imeni S.S. Korsakova","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2023-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"10583685","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
[Gut microbiota in patients with relapsing-remitting multiple sclerosis]. [复发缓解型多发性硬化症患者的肠道微生物群]。
Q3 Medicine Pub Date : 2023-01-01 DOI: 10.17116/jnevro20231230118
M V Tardov, Sh Talapbek, N V Sturov, E V Popova, A V Boldin, E I Rusanova, N N Suvorova

Microorganisms in human life play a huge role: in particular, those that coexist with the host organism, inhabiting the skin, upper respiratory tract, external genitalia and especially the digestive tract. The intestinal microbiota, including bacteriome, mycobiome and virome, not only takes part in the digestion process, but also provides the synthesis of a number of vitamins. The intestinal microbiome also serves as the basis for a system of extensive bidirectional neuroendocrine pathways that connect microbiota with various regions of the central nervous system, the hypothalamic-pituitary-adrenal system, and the peripheral parts of the autonomic nervous system. This system of connections has got the name of gut-brain axis and has attracted close attention of scientists over the past two decades, since a targeted impact on the intestinal flora is potentially capable of changing the nature of nervous system regulatory influences on the whole body. It is especially important to study patterns of functioning of the gut-brain axis in patients with the nervous system pathology, namely neurodegenerative and demyelinating diseases. Methods for their treatment continue to improve, and perhaps the correction of the gut microbiotic composition will serve as an additional therapeutic approach. The review article describes current views on the role of the intestinal microbiota, provides the latest data on the composition of bacteriome, mycobiome, and virome in patients with relapsing-remitting multiple sclerosis.

微生物在人类生活中发挥着巨大的作用:特别是那些与宿主生物共存的微生物,栖息在皮肤、上呼吸道、外生殖器,尤其是消化道。肠道微生物群,包括细菌组、真菌组和病毒组,不仅参与消化过程,而且还提供多种维生素的合成。肠道微生物群也是一个广泛的双向神经内分泌通路系统的基础,该系统将微生物群与中枢神经系统的各个区域、下丘脑-垂体-肾上腺系统和自主神经系统的外周部分联系起来。这种连接系统被称为肠脑轴,在过去的二十年中引起了科学家们的密切关注,因为对肠道菌群的定向影响可能会改变神经系统对整个身体的调节影响的性质。研究神经系统病变,即神经退行性和脱髓鞘疾病患者肠-脑轴的功能模式尤为重要。他们的治疗方法不断改进,也许肠道微生物组成的纠正将作为一种额外的治疗方法。这篇综述文章描述了目前对肠道微生物群作用的看法,提供了复发-缓解型多发性硬化症患者中细菌组、真菌组和病毒组组成的最新数据。
{"title":"[Gut microbiota in patients with relapsing-remitting multiple sclerosis].","authors":"M V Tardov,&nbsp;Sh Talapbek,&nbsp;N V Sturov,&nbsp;E V Popova,&nbsp;A V Boldin,&nbsp;E I Rusanova,&nbsp;N N Suvorova","doi":"10.17116/jnevro20231230118","DOIUrl":"https://doi.org/10.17116/jnevro20231230118","url":null,"abstract":"<p><p>Microorganisms in human life play a huge role: in particular, those that coexist with the host organism, inhabiting the skin, upper respiratory tract, external genitalia and especially the digestive tract. The intestinal microbiota, including bacteriome, mycobiome and virome, not only takes part in the digestion process, but also provides the synthesis of a number of vitamins. The intestinal microbiome also serves as the basis for a system of extensive bidirectional neuroendocrine pathways that connect microbiota with various regions of the central nervous system, the hypothalamic-pituitary-adrenal system, and the peripheral parts of the autonomic nervous system. This system of connections has got the name of gut-brain axis and has attracted close attention of scientists over the past two decades, since a targeted impact on the intestinal flora is potentially capable of changing the nature of nervous system regulatory influences on the whole body. It is especially important to study patterns of functioning of the gut-brain axis in patients with the nervous system pathology, namely neurodegenerative and demyelinating diseases. Methods for their treatment continue to improve, and perhaps the correction of the gut microbiotic composition will serve as an additional therapeutic approach. The review article describes current views on the role of the intestinal microbiota, provides the latest data on the composition of bacteriome, mycobiome, and virome in patients with relapsing-remitting multiple sclerosis.</p>","PeriodicalId":24030,"journal":{"name":"Zhurnal nevrologii i psikhiatrii imeni S.S. Korsakova","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2023-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"10590412","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 1
[Insomnia in neurological patients with disabilities]. [神经系统残疾患者的失眠]。
Q3 Medicine Pub Date : 2023-01-01 DOI: 10.17116/jnevro202312302112
E A Korabelnikova, A N Akavov, M L Baranov

Sleep is the most important factor reflecting the level of psychophysical well-being of a person and influencing him/her to the same extent. The greater susceptibility to sleep disturbances in patients with disabilities is associated with numerous factors. In the existing literature, there are few studies of insomnia in people with neurological disabilities. This article presents a current view on sleep disorders in disabled people and methods for their treatment.

睡眠是反映一个人身心健康水平的最重要因素,对其影响程度相同。残疾患者对睡眠障碍的更大易感性与许多因素有关。在现有的文献中,很少有关于神经障碍患者失眠的研究。本文介绍了目前对残疾人睡眠障碍的看法及其治疗方法。
{"title":"[Insomnia in neurological patients with disabilities].","authors":"E A Korabelnikova,&nbsp;A N Akavov,&nbsp;M L Baranov","doi":"10.17116/jnevro202312302112","DOIUrl":"https://doi.org/10.17116/jnevro202312302112","url":null,"abstract":"<p><p>Sleep is the most important factor reflecting the level of psychophysical well-being of a person and influencing him/her to the same extent. The greater susceptibility to sleep disturbances in patients with disabilities is associated with numerous factors. In the existing literature, there are few studies of insomnia in people with neurological disabilities. This article presents a current view on sleep disorders in disabled people and methods for their treatment.</p>","PeriodicalId":24030,"journal":{"name":"Zhurnal nevrologii i psikhiatrii imeni S.S. Korsakova","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2023-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"10791416","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
[Comparison of psychometric and pathopsychological approaches in the assessment of intellectual activity in children and adolescents with progressive forms of schizophrenia]. [心理测量法和病理心理学方法在评估儿童和青少年进行性精神分裂症智力活动中的比较]。
Q3 Medicine Pub Date : 2023-01-01 DOI: 10.17116/jnevro2023123021120
S E Strogova, N V Zvereva, A I Khromov, N V Simashkova

Objective: To study the intellectual activity of children and adolescents with progressive forms of schizophrenia using quantitative and qualitative diagnostic methods.

Material and methods: An experimental group consisted of 67 children and adolescents (mean age 11.1±2.8 years) with mental pathology of schizophrenia spectrum with varying severity of the disease (malignant, progressive, and low progressive course) and leading clinical syndromes (catatonic, psychopathic, neurosis-like, and hyperkinetic). A control group included 63 children and adolescents (mean age 11.1±3.0 years) without a verified psychiatric diagnosis, secondary schools' students. The Wechsler Intelligence Scale for Children (WISC) was used for assessing intelligence, the Design of objects method was used for assessing the characteristics of thinking.

Results: The relationship between thinking disorders and the parameters of verbal intelligence in patients with schizophrenia was shown (the Information subtest is related to all Object Construction parameters, r=0.401 to r=0.634; verbal IQ score is associated with some Object Construction scores, r=0.541 to r=0.537). In the control group, such a relationship was not noted. A decrease in the level of intelligence and severe thinking disorders is associated with such clinical factors as the malignant course of the disease (mean Full IQ score is 60.1, z-value of the coefficient of standardization in relation to the age norm is -2.1) and catatonic syndrome (mean Full IQ score is 68.1, coefficient of standardization is 60%).

Conclusion: The use of psychometric and pathopsychological approaches in the diagnosis of intellectual activity complements each other.

目的:应用定量和定性诊断方法研究儿童青少年进行性精神分裂症的智力活动。材料和方法:实验组包括67名儿童和青少年,平均年龄11.1±2.8岁,精神分裂症精神病理谱具有不同的疾病严重程度(恶性、进行性和低进行性病程)和主要临床综合征(紧张性、精神病性、神经症样和多动性)。对照组包括63名未确诊精神疾病的儿童和青少年(平均11.1±3.0岁)、中学生。采用韦氏儿童智力量表(WISC)评估智力,采用对象设计法评估思维特征。结果:精神分裂症患者的思维障碍与言语智力参数存在相关性(信息子测验与所有客体建构参数均相关,r=0.401 ~ r=0.634;语言智商得分与某些对象构建得分相关,r=0.541至r=0.537)。在对照组中,没有注意到这种关系。智力水平下降和严重思维障碍与疾病病程(Full IQ均值60.1,相对于年龄常值的标准化系数z值为-2.1)、紧张性综合征(Full IQ均值68.1,标准化系数为60%)等临床因素有关。结论:心理测量法与病理心理学方法在智力活动诊断中的作用是互补的。
{"title":"[Comparison of psychometric and pathopsychological approaches in the assessment of intellectual activity in children and adolescents with progressive forms of schizophrenia].","authors":"S E Strogova,&nbsp;N V Zvereva,&nbsp;A I Khromov,&nbsp;N V Simashkova","doi":"10.17116/jnevro2023123021120","DOIUrl":"https://doi.org/10.17116/jnevro2023123021120","url":null,"abstract":"<p><strong>Objective: </strong>To study the intellectual activity of children and adolescents with progressive forms of schizophrenia using quantitative and qualitative diagnostic methods.</p><p><strong>Material and methods: </strong>An experimental group consisted of 67 children and adolescents (mean age 11.1±2.8 years) with mental pathology of schizophrenia spectrum with varying severity of the disease (malignant, progressive, and low progressive course) and leading clinical syndromes (catatonic, psychopathic, neurosis-like, and hyperkinetic). A control group included 63 children and adolescents (mean age 11.1±3.0 years) without a verified psychiatric diagnosis, secondary schools' students. The Wechsler Intelligence Scale for Children (WISC) was used for assessing intelligence, the Design of objects method was used for assessing the characteristics of thinking.</p><p><strong>Results: </strong>The relationship between thinking disorders and the parameters of verbal intelligence in patients with schizophrenia was shown (the Information subtest is related to all Object Construction parameters, <i>r</i>=0.401 to <i>r</i>=0.634; verbal IQ score is associated with some Object Construction scores, <i>r</i>=0.541 to <i>r</i>=0.537). In the control group, such a relationship was not noted. A decrease in the level of intelligence and severe thinking disorders is associated with such clinical factors as the malignant course of the disease (mean Full IQ score is 60.1, z-value of the coefficient of standardization in relation to the age norm is -2.1) and catatonic syndrome (mean Full IQ score is 68.1, coefficient of standardization is 60%).</p><p><strong>Conclusion: </strong>The use of psychometric and pathopsychological approaches in the diagnosis of intellectual activity complements each other.</p>","PeriodicalId":24030,"journal":{"name":"Zhurnal nevrologii i psikhiatrii imeni S.S. Korsakova","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2023-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"10798352","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
期刊
Zhurnal nevrologii i psikhiatrii imeni S.S. Korsakova
全部 Acc. Chem. Res. ACS Applied Bio Materials ACS Appl. Electron. Mater. ACS Appl. Energy Mater. ACS Appl. Mater. Interfaces ACS Appl. Nano Mater. ACS Appl. Polym. Mater. ACS BIOMATER-SCI ENG ACS Catal. ACS Cent. Sci. ACS Chem. Biol. ACS Chemical Health & Safety ACS Chem. Neurosci. ACS Comb. Sci. ACS Earth Space Chem. ACS Energy Lett. ACS Infect. Dis. ACS Macro Lett. ACS Mater. Lett. ACS Med. Chem. Lett. ACS Nano ACS Omega ACS Photonics ACS Sens. ACS Sustainable Chem. Eng. ACS Synth. Biol. Anal. Chem. BIOCHEMISTRY-US Bioconjugate Chem. BIOMACROMOLECULES Chem. Res. Toxicol. Chem. Rev. Chem. Mater. CRYST GROWTH DES ENERG FUEL Environ. Sci. Technol. Environ. Sci. Technol. Lett. Eur. J. Inorg. Chem. IND ENG CHEM RES Inorg. Chem. J. Agric. Food. Chem. J. Chem. Eng. Data J. Chem. Educ. J. Chem. Inf. Model. J. Chem. Theory Comput. J. Med. Chem. J. Nat. Prod. J PROTEOME RES J. Am. Chem. Soc. LANGMUIR MACROMOLECULES Mol. Pharmaceutics Nano Lett. Org. Lett. ORG PROCESS RES DEV ORGANOMETALLICS J. Org. Chem. J. Phys. Chem. J. Phys. Chem. A J. Phys. Chem. B J. Phys. Chem. C J. Phys. Chem. Lett. Analyst Anal. Methods Biomater. Sci. Catal. Sci. Technol. Chem. Commun. Chem. Soc. Rev. CHEM EDUC RES PRACT CRYSTENGCOMM Dalton Trans. Energy Environ. Sci. ENVIRON SCI-NANO ENVIRON SCI-PROC IMP ENVIRON SCI-WAT RES Faraday Discuss. Food Funct. Green Chem. Inorg. Chem. Front. Integr. Biol. J. Anal. At. Spectrom. J. Mater. Chem. A J. Mater. Chem. B J. Mater. Chem. C Lab Chip Mater. Chem. Front. Mater. Horiz. MEDCHEMCOMM Metallomics Mol. Biosyst. Mol. Syst. Des. Eng. Nanoscale Nanoscale Horiz. Nat. Prod. Rep. New J. Chem. Org. Biomol. Chem. Org. Chem. Front. PHOTOCH PHOTOBIO SCI PCCP Polym. Chem.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1